Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose

1995 ◽  
Vol 82 (3) ◽  
pp. 445-452 ◽  
Author(s):  
Marc Levivier ◽  
Serge Goldman ◽  
Benoît Pirotte ◽  
Jean-Marie Brucher ◽  
Danielle Balériaux ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Stereotactic Biopsy ◽  
Diagnostic Yield ◽  
Brain Biopsy ◽  
Emission Tomography ◽  
Stereotactic Brain Biopsy ◽  
Ct Guided ◽  
Content Type ◽  
Positron Emission

✓ The aim of the present study was to determine whether routine integration of positron emission tomography (PET) with 18F-labeled fluorodeoxyglucose (FDG) in the planning of stereotactic brain biopsy increases the technique's diagnostic yield. Forty-three patients underwent combined FDG-PET— and computerized tomography (CT)-guided stereotactic biopsy of intracranial lesions according to a previously described technique. In 36 patients, an area of abnormal FDG uptake was used to guide at least one stereotactic biopsy trajectory. A total of 90 stereotactic trajectories were performed; among them, 55 were based on FDG-PET—defined targets and 35 were based on CT-defined targets. Histological diagnosis was obtained in all patients, but six of the 90 trajectories were nondiagnostic; all six were based on targets defined by CT only. Differences between the diagnostic yield of trajectories based on FDG-PET—defined targets and those based on CT-defined targets were statistically significant in patients with contrast-enhanced lesions, but not in patients with nonenhancing lesions. These results support the view the FDG-PET may contribute to the successful management of brain tumor patients requiring stereotactic biopsy. Because no significant increase in discomfort or morbidity related to the technique was found, it is suggested that the development of similar techniques integrating PET data in the planning of stereotactic biopsy should be considered by centers performing stereotactic surgery and having access to PET technology.

Fluorine-18—labeled fluorodeoxyglucose—positron emission tomography studies of acute brainstem Lyme neutoborreliosis

2005 ◽  
Vol 102 (5) ◽  
pp. 927-929 ◽  
Author(s):  
Michail Plotkin ◽  
Hubertus Hautzel ◽  
Bernd Joachim Krause ◽  
Stephan Mohr ◽  
Karl Josef Langen ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Magnetic Resonance Images ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Brainstem Tumor ◽  
Content Type ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission ◽  
Fine Print

✓ The authors report on a patient suffering from acute Lyme borreliosis who underwent two consecutive [18F]fluorodeoxyglucose—positron emission tomography (FDG-PET) studies demonstrating the course of the disease. The first FDG-PET study revealed markedly increased glucose metabolism in the brainstem, matching exactly the signal abnormalities exhibited on magnetic resonance images and indicating a brainstem tumor. A second PET scan demonstrated no abnormality in this region, thus reflecting clinical remission following antibiotic therapy. Data in the present case indicate that hypermetabolic findings on FDG-PET studies in the brainstem region should be regarded with caution and that neuroborreliosis must be considered as a possible differential diagnosis.

Positron Emission Tomography-Guided Stereotactic Brain Biopsy

Neurosurgery ◽  
1992 ◽  
Vol 31 (4) ◽  
pp. 792-797 ◽  
Author(s):  
Marc Levivier ◽  
Serge Goldman ◽  
Luc M. Bidaut ◽  
André Luxen ◽  
Etienne Stanus ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Brain Biopsy ◽  
Emission Tomography ◽  
Stereotactic Brain Biopsy ◽  
Positron Emission

scholarly journals Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

2020 ◽  
Author(s):  
Nana Luo ◽  
Dan Ruan ◽  
Yi-zhen Pang ◽  
Qi-hang Shang ◽  
Hao-jun Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Prostate Biopsy ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Ct Guided ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background Biopsy is considered the gold-standard technique for prostate cancer diagnosis and is recommended in patients with a high clinical indication of prostate cancer. In this study, we aimed to determine the diagnostic efficacy of a novel positron emission tomography (PET)/computed tomography (CT)-guided percutaneous trans-pararectal space-based approach to targeted prostate biopsy.Methods PET/CT-guided percutaneous trans-pararectal space prostate biopsies were performed in 14 consecutive patients with indications of prostate cancer. Whole-body 18 F-FDG PET/CT indicated the presence of 18 F-fluorodeoxyglucose (FDG)-avid focal prostate lesions. Two tissue specimens were obtained from each patient. The final diagnoses were established based on the results of a histopathological analysis and clinical follow-up, and these findings were used to verify the diagnostic accuracy of 18 F-FDG PET/CT for prostate cancer.Results The diagnostic accuracy of 18 F-FDG PET/CT for prostate cancer was 81.8%. Further analyses of the two biopsied samples per patient led to confirmed histopathological and immunohistochemical diagnoses of prostate cancer in all 14 patients. Consequently, the success rate of PET/CT-guided percutaneous trans-pararectal space prostate-targeted biopsy for the diagnosis of prostate cancer was 100.0% (14/14). Regarding safety, the average duration of biopsy was 20 min, and no serious complications occurred.Conclusions PET/CT-guided percutaneous trans-pararectal space prostate biopsy may yield a new approach to targeted prostate biopsy for the diagnosis of prostate cancer. Moreover, this biopsy procedure can be performed safely without complications, and is more cost-effective than conventional trans-rectal and trans-perineal prostate biopsy methods.

Combined magnetic resonance imaging– and positron emission tomography–guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients

2000 ◽  
Vol 8 (2) ◽  
pp. 1-6 ◽  
Author(s):  
Nicolas Massager ◽  
Philippe David ◽  
Serge Goldman ◽  
Benoît Pirotte ◽  
David Wikler ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Magnetic Resonance ◽  
Mr Imaging ◽  
Stereotactic Biopsy ◽  
Diagnostic Yield ◽  
Emission Tomography ◽  
Mass Lesion ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Mass Lesions

In the management of brainstem lesions, the place of stereotactic biopsy sampling remains debatable. The authors compared the results of magnetic resonance (MR) imaging, positron emission tomography (PET), and histological findings obtained in 30 patients who underwent an MR image– and PET-guided stereotactic biopsy procedure for a brainstem mass lesion. Between July 1991 and December 1998, 30 patients harboring a brainstem mass lesion underwent a stereotactic procedure in which combined MR imaging and PET guidance was used. Positron emission tomography scanning was performed using [18F]-fluorodeoxyglucose in 16 patients, methionine in two patients, and with both tracers in 12 patients. Definite diagnosis was established on histological examination of the biopsy samples. Interpretation of MR imaging findings only or PET findings only were in agreement with the histological diagnosis in 63% and 73% of cases, respectively. Magnetic resonance imaging and PET findings were concordant in 19 of the 30 cases; in those cases, imaging data correlated with histological findings in 79%. In seven patients who underwent one PET-defined and one MR imaging–defined trajectory, at histological examination the PET-guided samples were more representative of the tumor's nature and grade than the MR imaging–guided samples in four cases (57%). In 18 patients PET scanning was used to define a biopsy target and provided a diagnostic yield in 100% of the cases. Although the use of combined PET and MR imaging improves radiological interpretation of a mass lesion in the brainstem, it does not accurately replace histological diagnosis that is provided by a stereotactically obtained biopsy sample. Combined information provided by MR imaging and PET in stereotactic conditions improves the accuracy of targeting and the diagnostic yield of the stereotactically biopsy sample; an MR imaging– and PET-guided stereotactic biopsy procedure is a safe and efficient modality for the management of mass lesions of the brainstem.

Combined MRI and PET imaging in brain stem mass lesions: diagnostic yield in a series of 30 stereotactically biopsied patients

2000 ◽  
Vol 93 (6) ◽  
pp. 951-957 ◽  
Author(s):  
Nicolas Massager ◽  
Philippe David ◽  
Serge Goldman ◽  
Benoît Pirotte ◽  
David Wikler ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Stereotactic Biopsy ◽  
Diagnostic Yield ◽  
Emission Tomography ◽  
Histological Findings ◽  
Content Type ◽  
Positron Emission ◽  
Pet Scanning ◽  
Mass Lesions ◽  
Fine Print

Object. In the management of brainstem lesions, the place of stereotactic biopsy sampling remains debatable. The authors compared the results of magnetic resonance (MR) imaging, positron emission tomography (PET) scanning, and histological studies obtained in 30 patients who underwent MR imaging— and PET-guided stereotactic biopsy procedures for a brainstem mass lesion.Methods. Between July 1991 and December 1998, 30 patients harboring brainstem mass lesions underwent a stereotactic procedure in which combined MR imaging and PET scanning guidance were used. Positron emission tomography scanning was performed using [18F]fluorodeoxyglucose in 16 patients, methionine in two patients, and both tracers in 12 patients. Definite diagnosis was established on histological examination of the biopsy samples. Interpretation of MR imaging findings only or PET findings only was in agreement with the histological diagnosis in 63% and 73% of cases, respectively. Magnetic resonance imaging and PET findings were concordant in 19 of the 30 cases; in those cases, imaging data correlated with histological findings in 79%. Treatment based on information derived from MR imaging was concordant with therapy based on histological findings in only 17 patients (57%). Combining MR imaging and PET scanning data, the concordance between the neuroimaging-based treatment and treatments based on histological findings increased to 19 patients (63%). In seven patients who underwent biopsy procedures with one PET-defined and one MR imaging—defined trajectory, at histological examination the PET-guided samples were more representative of the tumor's nature and grade than the MR imaging—guided samples in four cases (57%). In 18 patients PET scanning was used to define a biopsy target and provided a diagnostic yield in 100% of the cases.Conclusions. Although the use of combined PET and MR imaging improves radiological interpretation of a mass lesion in the brainstem, it does not accurately replace histological diagnosis that is provided by a stereotactically obtained biopsy sample. Combining information provided by MR imaging and PET scanning in stereotactic conditions improves the accuracy of targeting and the diagnostic yield of the biopsy sample; an MR imaging— and PET-guided stereotactic biopsy procedure is a safe and efficient modality for the management of mass lesions of the brainstem.

Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging—guided stereotactic biopsy sampling of gliomas

2003 ◽  
Vol 99 (3) ◽  
pp. 474-479 ◽  
Author(s):  
Toshihiko Hara ◽  
Tatsuya Kondo ◽  
Tetsuo Hara ◽  
Noboru Kosaka
Keyword(s):  
Positron Emission Tomography ◽  
Contrast Agents ◽  
Anaplastic Astrocytoma ◽  
Stereotactic Biopsy ◽  
Emission Tomography ◽  
Content Type ◽  
Positron Emission ◽  
Pet Scanning ◽  
Pet Scans ◽  
Fine Print

Object. Neuroimaging-guided stereotactic biopsy procedures are commonly used for diagnosis of gliomas. A number of the imaging modalities currently in use are not reliable enough in depicting these tumors. The authors developed 18F-choline and 11C-choline as tumor imaging agents for positron emission tomography (PET) scanning, and used them to visualize gliomas prior to stereotactic biopsy procedures. Methods. The PET studies were performed in 12 patients who were thought to be affected by gliomas observed on computerized tomography and magnetic resonance images. The 18F- and 11C-choline were injected separately, and the PET scanning was started 5 and 20 minutes postinjection. The PET scans gave quantitative information about the distribution of 18F- and 11C-choline in the brain. The tumor uptake was constant between 5 and 20 minutes with both agents. Stereotactic biopsy sampling was performed to obtain tissues from the most radioactive areas on the PET scan; histological diagnoses were made using these tissues. The results were as follows: oligodendroglioma was found in two patients, astrocytoma in one, anaplastic astrocytoma in two, and glioblastoma in seven. Conclusions. The uptake of contrast agents was always low in low-grade gliomas, and the uptake in high-grade glioma was always high. The tumor/normal (T/N) ratio of 18F-choline was 10.5:12 in anaplastic astrocytoma and 13.2:21 in glioblastoma. The 18F-choline yielded slightly superior results compared with 11C-choline with regard to the T/N ratio. In one case of oligodendroglioma the tumor showed no uptake of 18F- and 11C-choline. With this exception, the PET scans of gliomas in which 18F- and 11C-choline contrast agents were added would guide the approach to the most malignant areas for stereotactic biopsy sampling.

Positron Emission Tomography-Guided Stereotactic Brain Biopsy

Neurosurgery ◽  
1992 ◽  
Vol 31 (4) ◽  
pp. 792-797 ◽  
Author(s):  
Marc Levivier ◽  
Serge Goldman ◽  
Luc M. Bidaut ◽  
André Luxen ◽  
Etienne Stanus ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Brain Biopsy ◽  
Emission Tomography ◽  
Stereotactic Brain Biopsy ◽  
Positron Emission

Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography—guided stereotactic brain biopsies

2004 ◽  
Vol 101 (3) ◽  
pp. 476-483 ◽  
Author(s):  
Benoit Pirotte ◽  
Serge Goldman ◽  
Nicolas Massager ◽  
Philippe David ◽  
David Wikler ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Gray Matter ◽  
Stereotactic Biopsy ◽  
Emission Tomography ◽  
Content Type ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Target Definition ◽  
Met Pet ◽  
Fine Print

Object. The aim of this study was to compare the contribution of the tracers 11C-methionine (Met) and 18F-fluorodeoxyglucose (FDG) in positron emission tomography (PET)—guided stereotactic brain biopsy. Methods. Forty-five patients underwent combined Met-PET and FDG-PET studies associated with computerized tomography (CT)— or magnetic resonance (MR)—guided stereotactic biopsy. Each patient presented with a lesion that was in proximity to the cortical or subcortical gray matter. The Met-PET and FDG-PET scans were analyzed to determine which tracer offers the best information to guide at least one stereotactic biopsy trajectory. Histologically based diagnoses were rendered in all patients (39 tumors, six nontumorous lesions) and biopsies were performed in all tumors with the aid of PET guidance. When tumor FDG uptake was higher than that in the gray matter (18 tumors), FDG was used for target definition. When FDG uptake was absent or equivalent to that in the gray matter (21 tumors), Met was used for target definition. Parallel review of all histological and imaging data showed that all tumors had an area of abnormal Met uptake and 33 had abnormal FDG uptake. All six nontumorous lesions had no Met uptake and biopsies were performed using CT or MR guidance only. All tumor trajectories had an area of abnormal Met uptake; all nondiagnostic trajectories in tumors had no abnormal Met uptake. Conclusions. When FDG shows limitations in target selection, Met is a good alternative because of its high specificity in tumors. Moreover, in the context of a single-tracer procedure and regardless of FDG uptake, Met is a better choice for PET guidance in neurosurgical procedures.

Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study

1997 ◽  
Vol 86 (2) ◽  
pp. 241-251 ◽  
Author(s):  
Marvin Bergsneider ◽  
David A. Hovda ◽  
Ehud Shalmon ◽  
Daniel F. Kelly ◽  
Paul M. Vespa ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Positron Emission Tomography ◽  
Brain Injury ◽  
Head Injury ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Content Type ◽  
Cerebral Metabolic Rate ◽  
Positron Emission ◽  
Fine Print

✓ Experimental traumatic brain injury studies have shown that cerebral hyperglycolysis is a pathophysiological response to injury-induced ionic and neurochemical cascades. This finding has important implications regarding cellular viability, vulnerability to secondary insults, and the functional capability of affected regions. Prior to this study, posttraumatic hyperglycolysis had not been detected in humans. The characteristics and incidence of cerebral hyperglycolysis were determined in 28 severely head injured patients using [18F]fluorodeoxyglucose—positron emission tomography (FDG-PET). The local cerebral metabolic rate of glucose (CMRG) was calculated using a standard compartmental model. In six of the 28 patients, the global cerebral metabolic rate of oxygen (CMRO2) was determined by the simultaneous measurements of arteriovenous differences of oxygen and cerebral blood flow (xenon-133). Hyperglycolysis, defined as an increase in glucose utilization that measures two standard deviations above expected levels, was documented in all six patients in whom both FDG-PET and CMRO2 determinations were made within 8 days of injury. Five additional patients were found to have localized areas of hyperglycolysis adjacent to focal mass lesions. Within the 1st week following the injury, 56% of patients studied had presumptive evidence of hyperglycolysis. The results of this study indicate that the metabolic state of the traumatically injured brain should be defined differentially in terms of glucose and oxygen metabolism. The use of FDG-PET demonstrates that hyperglycolysis occurs both regionally and globally following severe head injury in humans. The results of this clinical study directly complement those previously reported in experimental brain-injury studies, indicating the capability of imaging a fundamental component of cellular pathophysiology characteristic of head injury.

Sign in / Sign up

Export Citation Format

Share Document